

Table SI. Demographic and clinical variables in patients treated with different types of anticancer agents

	Total	Chemotherapy type				Non-targeted therapy only (n = 266)
		Targeted agents				
		EGFRIs (n = 23)	VEGFRIs (n = 34)	HER2Is (n = 31)	Other TIs (n = 21)	
Sex, n						
Male	154	12	20	4	11	108
Female	220	11	14	27	10	158
Age, years, mean ± standard error		60.87 ± 2.18	57.71 ± 2.27	51.39 ± 1.89	59.00 ± 2.53	56.43 ± 0.66
≤ 50 years	120	4	8	19	5	84
51–60 years	116	6	9	6	6	89
≥ 61 years	138	13	17	6	10	93
Duration of current chemotherapy, n						
≤ 12 weeks	137	5	8	5	11	108
13–24 weeks	108	4	3	11	5	85
≥ 25 weeks	129	14	23	15	5	73
First line chemotherapy, n						
Yes	322	18	31	23	21	230
No	52	5	3	8	0	36
Radiotherapy						
Yes	99	9	3	9	5	73
No	275	14	31	22	16	193
Previous history of itching: Yes, n	80	3	7	5	2	63
Rash, n						
Yes	72	16 ***	8	6	1	41
Head	39	10 ***	6	2	0	21
Neck	13	2	2	1	1	7
Shoulder	11	3 *	3 *	1	0	4
Chest	16	4 **	4 *	1	0	7
Abdomen	11	1	1	2	0	7
Upper back	19	7 ***	3	0	0	9
Lower back	8	3 *	1	0	0	4
Arm	20	8 ***	0	2	0	10
Leg	22	9 ***	2	1	0	10
Cancer type, n						
Breast cancer	136	7	0	26	4	99
Colorectal cancer	113	10	28	0	0	75
Gastric cancer	33	1	1	5	0	26
Lung cancer	21	4	0	0	1	16
Haematologic malignancy	18	0	0	0	13	5
Other cancer	53	1	5	0	3	45

*** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ compared to non-targeted therapy only.

EGFRIs: epidermal growth factor receptor inhibitors, HER2Is: human epidermal growth factor receptor 2 inhibitors, Other TIs: other target inhibitors, VEGFRIs: vascular endothelial growth factor receptor inhibitors